Is obeticholic acid suitable for primary biliary cirrhosis?

Primary biliary cirrhosis/primary biliary cholangitis (Primary Biliary Cholangitis (PBC)) is a chronic liver disease characterized by immune-mediated bile duct destruction. If not controlled in time, it may progress to liver fibrosis or cirrhosis. Obeticholic acid (Obeticholic acid), as a new FXR receptor agonist, is considered to be one of the important drugs for the treatment of primary biliary cholangitis. Its main mechanism of action is to reduce hepatic bile acid synthesis and promote its efflux by activating farnesoid X receptors, thereby reducing liver cell damage caused by cholestasis.

Overseas, obeticholic acid is often recommended for patients with primary biliary cholangitis who have an inadequate response to or intolerance to ursodeoxycholic acid (UDCA). UDCA is the first-line treatment for primary biliary cholangitis, but some patients have limited efficacy in long-term treatment. At this time, obeticholic acid can be used as a single drug or combination treatment option. Its function is to improve biochemical indicators, reduce the inflammatory response caused by bile acid accumulation, and help delay disease progression.

However, obeticholic acid is not suitable for all patients with primary biliary cholangitis. For patients with decompensated cirrhosis or severe cholestasis, its use needs to be cautious because drug metabolism depends on liver function, and liver dysfunction may increase the risk of drug-related adverse reactions. In overseas clinical applications, doctors usually adjust the dose according to the patient's liver function grade (such asChild-Pugh score) to ensure safety.

Overall, obeticholic acid is an important treatment option for patients with early-to-mid-stage PBCEspecially for patients with poor response to UDCA, it can significantly improve biochemical indicators and slow down the worsening trend of the disease. In the future, as the drug is approved in more countries and related research deepens, its application prospects in Chinese patient groups are worth looking forward to.

Reference materials:https://en.wikipedia.org/wiki/Obeticholic_acid